Related Experiment Videos
[A pilot study of low-dose TS-1 and cisplatin combination chemotherapy for advanced gastric cancer]
T Kamata1, Y Hayashi, G Minatoya
1Dept. of Surgery and Gastroenterology, Keiju Medical Center.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 30, 2001
Abstract:
TS-1, a novel oral formation of 5-fluorouracil, consists of tegafur (5-FU), CDHP and Oxo. Low-dose cisplatin (CDDP) and TS-1 was evaluated in 12 patients with advanced or recurrent gastric cancer. CDDP was given biweekly at a dose of 15 mg/m2 infused for 30 minutes, and 80 mg/body of TS-1 was orally administered as many times as possible. The response rate was 41.7%. Median survival time was 13.3 months. In one case, an adverse reaction of grade 3 leucopenia was observed. Thus, thought it is necessary to watch for leucopenia, this chemotherapy could well be effective for patients with advanced or recurrent gastric cancer.